5 Million People Suffer from Strokes in the U.S.

CVBT has focused most intensely on developing new treatments that can stimulate new blood vessel growth into ischemic muscle tissues. However, blocked blood vessels can also severely injure other tissue types including nerve and neural tissue. Stroke results from the same basic atherosclerotic process that causes coronary artery disease, but occurs in vessels that supply brain cells with blood.

When blood flow is restricted or blocked in blood vessels supplying the brain or in vessels located within the brain, stroke results. Stroke is the number three cause of death in the United States. In pre-clinical animal studies, FGF-1141 reduced the size of damaged brain tissue after a stroke. We are currently developing it as a potential new therapy to treat this condition.

Stroke treatment is a new medical indication for FGF-1141: we are attempting to address the question of growing new nerve cells with the drug, instead of growing new blood vessels. Numerous reports in scientific literature indicate that FGF-1141 is a potent neuroprotective agent and can stimulate the growth of nerve cells. This additional property of FGF-1141 indicates that it may have utility in medical conditions where nerve loss has occurred such as neuropathy (nerve pain) and stroke. We estimate that 10 million people suffer from neuropathy. Since neuropathy represents an unmet medical need in this country, we believe a drug that could successfully treat this condition would be a major breakthrough. We will, however, explore this new indication cautiously.

Review a scientific summary of the most current research results in this area.

< Back to Treatment Applications

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.